RxDoctor Payments Data

Lisa Farris

Nurse Practitioner · Birmingham, ALNPI 1316981913

Payments from drug & device makers

$5,004in general payments, 2019–2025

Across 61 payments — averaging $82.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
  • Akebia Therapeutics Inc$614
  • Fresenius USA Marketing, Inc.$267
  • AstraZeneca$207
  • Vifor Pharma, Inc.$183
  • Ardelyx, Inc.$121
  • plus $344 from 9 others

What the payments were for

  • Consulting fees$2,21044%
  • Travel & lodging$1,03221%
  • Food & beverage$1,76235%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,004 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$13,758
Medicare patients
60
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan15$299,238
Sevelamer Carbonate44$10,710
LokelmaSodium Zirconium Cyclosilicate13$10,076
ClinolipidFat Emulsion/Olive/Soy/Phospho32$9,537
FarxigaDapagliflozin Propanediol12$7,914
JardianceEmpagliflozin11$6,521
ProsolParenteral Amino Acid 20% No.122$3,698
Midodrine Hcl18$1,659
Hydralazine Hcl35$645
Amlodipine Besylate52$229
Carvedilol38$206
Potassium Chloride12$186
Minoxidil12$179
Losartan Potassium18$176
Furosemide17$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$26$299,23815 claims
AstraZenecaLokelma, Farxiga$207$17,99025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →